Ali, A., Ali, M., Hachim, S. (2022). The Level of Survivin in The Blood and Urine Samples of Bladder Cancer Patients Using the ELISA Method. The Egyptian Journal of Hospital Medicine, 89(2), 8065-8069. doi: 10.21608/ejhm.2022.277589
Aesha S. Ali; Mohammed R. Ali; Sadeq K. Hachim. "The Level of Survivin in The Blood and Urine Samples of Bladder Cancer Patients Using the ELISA Method". The Egyptian Journal of Hospital Medicine, 89, 2, 2022, 8065-8069. doi: 10.21608/ejhm.2022.277589
Ali, A., Ali, M., Hachim, S. (2022). 'The Level of Survivin in The Blood and Urine Samples of Bladder Cancer Patients Using the ELISA Method', The Egyptian Journal of Hospital Medicine, 89(2), pp. 8065-8069. doi: 10.21608/ejhm.2022.277589
Ali, A., Ali, M., Hachim, S. The Level of Survivin in The Blood and Urine Samples of Bladder Cancer Patients Using the ELISA Method. The Egyptian Journal of Hospital Medicine, 2022; 89(2): 8065-8069. doi: 10.21608/ejhm.2022.277589
The Level of Survivin in The Blood and Urine Samples of Bladder Cancer Patients Using the ELISA Method
1Department of Microbiology, College of Medicine, Kirkuk University, Kirkuk, Iraq
2Department of Microbiology, College of Medicine, Al-Nahrain University, Baghdad, Iraq.
3Department of Nursing, Institute of Medical Technology/Baghdad, Middle Technical University, Baghdad, Iraq
Abstract
Background: Survivin is a member of inhibitors of the apoptosis family (IAP), it is over-expressed in almost all cancers including bladder cancers in which it is excreted in urine. Objectives: to find the possible suitability of survivin in urine and blood as a novel prognostic and or predictive molecular marker in bladder carcinoma. Patients with methods: urine and serum samples were taken from five groups: healthy persons, patients who had non-neoplastic urinary tract problems, genitourinary cancers excluding bladder cancer, patients with discovered newly or recurrent superficial urinary bladder carcinoma and patients with muscle-invasive or metastatic bladder cancer. All were attendants of the Urology department at Al-Kadhimiya Teaching Hospital in Baghdad. Survivin levels were analyzed by ELISA test in urine and serum samples of the five groups Results: The level of survivin in the normal control group was below the cutoff value in serum (71.385 pg/ml) and cutoff value in urine (71.86 pg/ml) while in non-neoplastic urological conditions the level of the survivin was evaluated above the cutoff value in serum and urine in 1/6 of the cases. While it was evaluated in half of the patients with urological malignancies other than bladder cancer and it was increased above the cutoff volume in 73.68% in the serum of patients with superficial urinary carcinoma and 78.9% in the urine of the same group. Conclusions: specific and sensitive determination of urine and (or) serum survivin provides a simple, non-invasive diagnostic method to complement cytology and (or) other diagnostic markers in persons with new onset or recurrent urinary bladder carcinoma.